Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study.

ABSTRACT:

Importance

Anti-vascular endothelial growth factor treatment is the first-line therapy in the treatment of center-involving diabetic macular edema. Data on capillary perfusion changes under repeated treatment in a possibly compromised vascular network are limited.

Objective

To evaluate the association of repeated ranibizumab injections on macular perfusion in patients with diabetic macular edema.

Design, setting, and participants

This study analyzed prospectively collected data from the 12-month RESTORE core study and the 24-month open label RESTORE extension study, which assessed the efficacy and safety of ranibizumab in patients with visual impairment due to diabetic macular edema. Of 345 patients with center-involving diabetic macular edema who had enrolled in the

SUBMITTER: Karst SG 

PROVIDER: S-EPMC5876859 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature